article thumbnail

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Pharmaceutical Technology

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered orally.

Hormones 100
article thumbnail

Researchers identify potential new genetic target for cancer drugs

Drug Discovery World

Over 5,000 genetic variants that enable certain cancers to thrive were identified, along with a potential therapeutic target to treat or even prevent these cancers from developing. The team also uncovered a link between certain disruptive BAP1 variants and higher levels of IGF-1, a hormone and growth factor.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hormone exposure in the womb potentially linked to migraine risk in later life

Scienmag

Hormone levels in the womb before birth have been potentially linked to the risk of developing migraine in adulthood, reveals a new study of genetic and environmental information from the world’s largest database of twins.

article thumbnail

Exercise hormone may modulate genes associated with replication of novel coronavirus

Scienmag

Brazilian researchers observed that in uninfected adipocytes, the hormone irisin altered the expression of genes that regulate ACE-2, which encodes a protein to which the virus binds in order to invade human cells.

article thumbnail

Genetic biomarkers could personalise therapy for TNBC

Drug Discovery World

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

article thumbnail

New genetic target for male contraception identified

Medical Xpress

Discovery of a gene in multiple mammalian species could pave the way for a highly effective, reversible and non-hormonal male contraceptive for humans and animals.

article thumbnail

Study connects hormones we’re born with to lifetime risk for immunological diseases

Scienmag

Credit: Michigan State University Differences in biological sex can dictate lifelong disease patterns, says a new study by Michigan State University researchers that links connections between specific hormones present before and after birth with immune response and lifelong immunological disease development.